Artis BioSolutions

Artis BioSolutions launched in April 2025 as an advanced therapy CDMO focused on streamlining the discovery, development, and production of genetic medicines. The company acquired Landmark Bio—a Boston-based cell and gene therapy manufacturer—to expand its capabilities. Artis offers end-to-end services from process development through GMP manufacturing for complex biologics including cell & gene therapies and mRNA therapeutics. It does not develop its own drugs but enables biopharma partners to accelerate their pipelines by providing critical materials, analytical development expertise, tech transfer know-how, and scalable GMP infrastructure. Its leadership team has experience supporting over fifty APIs/CRMs into clinic/commercialization across multiple modalities.